Cambrex cements North Carolina presence with buildings purchase

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Zhaojinkang)
(Image: Getty/Zhaojinkang)

Related tags Manufacturing facility API

Cambrex, a small molecule and API manufacturer, announced it will expand to establish a ‘center of excellence’ for process and development of its API clinical supply.

The company will expand its site in High Point, North Carolina, by purchasing a 35,000-square-foot building it is currently leasing, as well as an adjacent 45,000-square-foot building. Both of these buildings will be fitted with kilo-scale and pilot-scale vessels.

This facility expansion is in response to the growing customer requirements for clinical supply manufacturing, according to the company. The center will also work on the development of new technologies and engineering solutions.

A spokesperson for Cambrex told us, “This gives us the opportunity to expand, adds additional capabilities and allows us the flexibility to meet future demand for our customers.”

Cambrex acquired PharmCore in 2016, now known as Cambrex High Point, to locate the company on this site.

In April of 2017, Cambrex announced that a $3.2m (€2.75m) construction project was completed on the site. This saw the completion of an 11,000-square-foot analytical laboratory and a new clinical manufacturing suite with 2000-liter reactors and a 0.6-square-meter dryer for clinical APIs.

 “In April 2018, we announced a new analytical research & development laboratory, in addition to an investment in new continuous flow technology. In May 2018, we completed a pilot plant expansion at the High Point facility,”​ said the spokesperson.

In total, Cambrex has invested $5m in renovating the Cambrex High Point site. The company says that the High Point facility produces complex active pharmaceutical ingredients (APIs) and intermediates that require multi-step synthetic processes.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more